

- Methocarbamol, 119, 473e-10t  
Methotrexate  
  action of, 103e-14, 641, 1960  
  adverse effects of, 103e-11t, 103e-14, 1960  
  anemia, 398  
  common, 2146t  
  cutaneous, 379, 380  
  fetal, 124e-4  
  folate deficiency, 647  
  hepatic, 622, 2025  
  in HIV infection, 1261  
  late, 620t, 622  
  myelopathy, 607t  
  neurologic, 622  
  prevention of, 2182  
  pulmonary, 1797  
  renal, 103e-11t, 103e-14  
  seizures, 607t, 1793  
  serious, 348t, 2130t, 2146t, 2182t  
  for bladder cancer, 577  
  for breast cancer, 530  
  contraindications to, 1964  
  drug interactions of, 42, 42t, 2130t  
   asparaginase, 103e-11t  
   NSAIDs, 103e-11t, 103e-14  
   probenecid, 103e-14  
   salicylates, 103e-14  
   sulfonamides, 246e-4t  
   trimethoprim, 246e-4t, 939t  
  for ectopic pregnancy, 338  
  in elderly patients, 2148–2149  
  for gestational trophoblastic disease, 124e-5, 597  
  for giant cell arteritis, 2189  
  for granulomatosis with polyangiitis, 2185  
  for head and neck cancer, 505  
  for IBD, 1960  
  for inflammatory myopathies, 2201  
  for morphea, 376  
  for MS, 2672  
  for osteosarcoma, 119e-3  
  for polymyalgia rheumatica, 2189  
  for primary central nervous system lymphoma, 601–602  
  for psoriasis, 348, 348t  
  for psoriatic arthritis, 2177  
  for reactive arthritis, 2175  
  for rheumatoid arthritis, 2145, 2146t, 2148  
  for sarcoidosis, 2211, 2212t  
  for SLE, 2130t, 2133  
  for systemic sclerosis, 2164, 2165  
  for Takayasu's arteritis, 2190  
  therapeutic monitoring of, 2146t, 2212t, 2765t  
  for vasculitis, 2182  
2-Methoxy estradiol, 102e-17f  
8-Methoxypsoralen, 391, 678  
Methyl aminolevulinate (MAL), 386  
Methylation, of DNA, 101e-4  
Methylation cycle, 642f  
2-Methylbutyryl-glycinuria, 434e-3t  
Methylcellulose, 1970t  
6-Methylcoumarin, 389t  
3-Methylcrotonyl glycinuria, 434e-3t  
α-Methyl dopa  
  adverse effects of, 253t, 727t, 2023, 2218t  
  for carcinoid syndrome, 567  
  for hypertension, 1624t  
  for hypertension in pregnancy, 46  
Methylene blue, 637, 656t  
5,10-Methylenetetrahydrofolate (5-MTHF), 641, 641t  
Methylenetetrahydrofolate reductase (MTHFR), 47, 641t, 642f, 643, 744  
Methylfolate trap, 641  
3-Methylglutaconic aciduria, 434e-3t  
2-Methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency, 434e-3t  
Methylmalonate, serum, 647  
Methylmalonic acidemia, 434e-2t, 434e-3t  
Methylmalonic acidemia/aciduria, congenital, 645  
Methylmalonyl CoA mutase deficiency, 645  
Methylnaltrexone, 61, 92  
7α-Methyl-19-nortestosterone, 2371  
Methylphenidate  
  for depression, 63  
  for fatigue, 63, 2672  
  for narcolepsy, 188t, 190  
  for opioid-induced drowsiness, 61  
Methylprednisolone  
  adverse effects of, 2130t  
  drug interactions of, 246e-3t  
  for giant cell arteritis, 2189  
  for gout, 2234  
  for Graves' ophthalmopathy, 2297  
  for IBD, 1960  
  for interstitial lung disease with diffuse alveolar hemorrhage, 1715  
  for MS, 2667, 2672  
  for nausea and vomiting, 260t  
  for optic neuritis, 202  
  for PCP, 1361t  
  for serum sickness, 667  
  for SLE, 2130t, 2132  
  for transplant rejection, 1828, 1829  
  for vertigo, 151t  
17-α-Methyl testosterone, 2370t, 2371  
5-Methyltetrahydrofolate, 641, 641t  
Methyl violet, 655  
Methylxanthines, 324, 473e-8t  
Methyprylon, 473e-11t  
Methysergide  
  adverse effects of, 1649, 2593, 2594t  
  for carcinoid syndrome, 566  
  for cluster headache prevention, 2595, 2595t  
  for exertional headache, 2597  
  for hypnic headache, 2598  
  for migraine prevention, 2593, 2594t  
  overdosage/poisoning with, 473e-8t  
Metoclopramide  
  adverse effects of, 260, 261, 2611  
  for constipation, 61  
  drug interactions of, 246e-2t  
  for gastroparesis, 260, 260t, 2427  
  for migraine, 2591, 2592t  
  for nausea and vomiting, 62, 103e-25, 474  
  parenteral, 2592t  
Metoprolol  
  for aortic dissection, 1641  
  for arrhythmias, 1479t, 1480t  
  dosage of, 1479t, 1480t  
  drug interactions of, 246e-12  
  genetic variations in response to, 39t, 40  
  for heart failure, 1512t  
  for hypertension, 1624t  
  for ischemic heart disease, 1589t  
  metabolism of, 34t  
  for migraine prevention, 2594t  
  for myocardial infarction, 1604  
  overdosage/poisoning with, 473e-9t  
  pharmacology of, 1479t, 1480t  
Metronidazole, 246e-5t, 246e-10  
Metronidazole  
  for acne rosacea, 352  
  action of, 931t, 932f, 933  
  adverse effects of, 246e-5t, 353, 938t, 944, 2687t  
  for amebiasis, 1367, 1367t  
  for anaerobic bacterial infections, 1101, 1101t  
  for bacterial vaginosis, 873t, 875  
  for *C. difficile* infection, 860, 860t  
  for clostridial infections, 991t, 994  
  for *D. fragilis* infection, 1409  
  drug interactions of, 246e-5t, 939t, 944  
  for epidural abscess, 767t  
  for febrile neutropenia, 103e-23  
  for *Giardia* infections, 268, 1406  
  in *H. pylori* eradication, 1042t, 1922, 1922t  
  for hepatic encephalopathy, 2066  
  indications for, 246e-5t, 941t, 944, 945t  
  for intraabdominal infections, 767t  
  for intracranial infections, 780t  
  for Ludwig's angina, 233  
  for meningitis, 887t, 889, 889t  
  for necrotizing fasciitis, 832t  
  for osteomyelitis, 841t  
  for pelvic inflammatory disease, 878, 878t  
  for peritonitis, 848  
  for postpartum endomyometritis, 50  
  for pouchitis in IBD, 1960  
  in pregnancy and lactation, 246e-5t, 937t  
  resistance to  
    in anaerobic bacteria, 1101  
    in *H. pylori*, 1042  
    mechanisms of, 931t, 934  
    prevalence of, 941t, 944  
  for *T. vaginalis* infection, 871, 873t, 874, 1409  
  for tetanus, 986  
  for Vincent's angina, 233  
METs (metabolic equivalent tasks), 1585t, 1587, 1587t  
Metyrapone, 611–612, 2273, 2318  
Mevalonate kinase, 372e-8t  
Mevalonate kinase deficiency, 2215  
Mexiletine  
  adverse effects of, 1480t, 2682t  
  for arrhythmias, 1480t, 1498  
  dosage of, 1480t  
  for hyperkalemic periodic paralysis, 462e-18  
  metabolism of, 34t  
  for myotonia, 462e-11  
  for neuropathy, 2682t  
  for pain, 95, 2672  
  for paramyotonia congenita, 462e-18  
  pharmacology of, 1480t  
Meyer's loop, 199  
Mezlocillin, 166e-3, 835  
MFC (minimal fungicidal concentration), 150e-9  
MGMT, 600  
MGUS. *See* Monoclonal gammopathy of undetermined significance (MGUS)  
MHC (major histocompatibility complex). *See* Human leukocyte antigen (HLA) complex  
MHC class-restricted T cells, 372e-18, 373e-3, 373e-4  
MHC-peptide complex, 373e-3  
MI. *See* Myocardial infarction (MI)  
Miasma, 761  
Mibefradil, 328  
MIC (minimal inhibitory concentration), 150e-9, 935  
*mic-2* gene, 119e-4  
MIC-A5.1 allele, 2346  
Micafungin, 233, 1331, 1344t, 1352t  
*MICA* gene, 1240t, 1241  
Mice. *See also* Rodent-borne viruses  
  bite-wounds, 167e-2  
  embryonic stem cells of, 454  
  gnotobiotic, 86e-7. *See also* Gut microbiota  
  knock-out/knock-in, 432  
  in rickettsialpox. *See* Rickettsialpox  
  transgenic, as models of genetic disease, 432  
Micelles, 1935, 2076  
Miconazole, 349, 873t, 875  
Microaerophilic bacteria, 1094  
Microalbuminuria  
  in chronic kidney disease, 1813  
  definition of, 1834t  
  in diabetic nephropathy, 1844, 2425, 2425f  
  in glomerular disease, 1834t  
  in HIV infection, 1258  
  in hypertension, 1616  
Microaneurysms, retinal, 40e-3  
Microangiopathic hemolytic anemia, 81e-4f, 282, 657, 657t, 726f. *See also* Thrombotic microangiopathy  
Microarray technology  
  in carcinoma of unknown primary, 120e-3  
  definition of, 769t  
  for gene expression in cancer, 101e-7, 101e-8f  
  in infectious disease diagnosis, 769t  
Microbial bioterrorism. *See* Bioterrorism  
Microbial pathogenesis, **145e-1**  
  avoidance of host defenses, 145e-4–7, 145e-4f, 145e-6f  
  entry and adherence, 145e-1–3  
  growth after entry, 145e-4  
  host receptors, 145e-2t, 145e-3  
  host response, 145e-10, 372e-23, 372e-26